The Nagoya Protocol to the Convention on Biological Diversity has been in the news lately as it
is currently on its way to being enacted into European Union legislation (see IPKat posts here
and here – and yes, I am the “Norman” who commented on those posts). So I’ve decided to post
some observations on the leaked draft TPP treaty proposed provisions dealing with genetic
resources, which I drafted in my spate of blogging on the TPP, but never got around to posting at
the time.
Understanding these provisions requires some background on the Nagoya Protocol to the
Convention on Biological Diversity. The Nagoya Protocol mandates a system in which the
benefits of exploitation of genetic resources are shared with the party providing that resource.
The basic idea is nothing novel. If company A wants access to a novel organism or compound X
owned by company B, A would normally enter into a material transfer agreement with B, which
might well require A to pay B royalties on any patented invention derived from X. The Nagoya
Protocol contemplates that if company A wants to, for example, go bioprospecting in the
Amazon rain forest, it would get prior consent from a competent national authority (Art 13) and
enter into an access and benefit sharing (ABS) agreement to share any benefits on mutually
agreed terms (Art 5). Traditional knowledge is treated in a similar way. In other words, the effect
is that countries would be deemed to own the genetic resources within their territory, and
company A seeking to exploit those would contract with the national authority over the terms of
access in the same way that it would contract with company B. A great deal of the Nagoya
Protocol describes the structure of this contracting process.